{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:39:47Z","timestamp":1775198387652,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research and Development of Chinese Capital Clinical Characteristic Applications","award":["Z151100004015025"],"award-info":[{"award-number":["Z151100004015025"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81930121"],"award-info":[{"award-number":["81930121"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Duchenne muscular dystrophy (DMD) is the most common genetic muscle disease in human. We aimed to describe the genotype distribution in a large cohort of Chinese DMD patients and their delayed loss of ambulation by glucocorticoid (GC) treatments. This is to facilitate protocol designs and outcome measures for the emerging DMD clinical trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1163 patients with DMD were recruited and genotyped. Genotype variations were categorized as large deletions, large duplications, and small mutations. Large deletions were further analyzed for those amenable to exon-skipping therapies. Participants aged 5\u00a0years or older were grouped into GC-treated and GC-na\u00efve groups. Clinical progression among different genotypes and their responses to GC treatments were measured by age at loss of ambulation (LOA). Among the mutation genotypes, large deletions, large duplications, and small mutations accounted for 68.79%, 7.14%, and 24.07%, respectively. The mean age at diagnosis was 4.59\u00a0years; the median ages at LOA for the GC-na\u00efve, prednisone\/prednisolone-treated, and deflazacort-treated groups were 10.23, 12.02, and 13.95\u00a0years, respectively. The \u201cdeletion amenable to skipping exon 44\u201d subgroup and the nonsense-mutation subgroup had older ages at LOA than the \u201cother deletions\u201d subgroup. Subgroups were further analyzed by both genotypes and GC status. All genotypes showed significant beneficial responses to GC treatment. Deletions amenable to skipping exon 44 showed a lower hazard ratio (0.155). The mean age at death was 18.57\u00a0years in this DMD group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Genotype variation influences clinical progression in certain DMD groups. Beneficial responses to GC treatment were observed among all DMD genotypes. Compared with other genotypes, deletions amenable to skipping exon 44 had a lower hazard ratio, which may indicate a stronger protective effect\u00a0of GC treatments on this subgroup. These data are valuable for designing future clinical trials, as clinical outcomes may be influenced by the genotypes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01837-x","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T18:15:06Z","timestamp":1619633706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy"],"prefix":"10.1186","volume":"16","author":[{"name":"National DMD Research Network of \u201cOne City, One Doctor\u201d","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongdong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuijie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1023-4073","authenticated-orcid":false,"given":"Shiwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"1837_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1055\/s-0035-1558982","volume":"35","author":"JF Brandsema","year":"2015","unstructured":"Brandsema JF, Darras BT. Dystrophinopathies. Semin Neurol. 2015;35:369\u201384.","journal-title":"Semin Neurol"},{"key":"1837_CR2","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","volume":"85","author":"L Bello","year":"2015","unstructured":"Bello L, Gordish-Dressman H, Morgenroth LP, Henricson EK, Duong T, Hoffman EP, et al. Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology. 2015;85:1048\u201355.","journal-title":"Neurology"},{"key":"1837_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-018-0853-z","volume":"13","author":"P Ma","year":"2018","unstructured":"Ma P, Zhang S, Zhang H, Fang S, Dong Y, Zhang Y, et al. Comprehensive genetic characteristics of dystrophinopathies in China. Orphanet J Rare Dis. 2018;13:109.","journal-title":"Orphanet J Rare Dis"},{"key":"1837_CR4","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/pds.4962","volume":"29","author":"J Wu","year":"2020","unstructured":"Wu J, Wang C, Toh S, Pisa FE, Bauer L. Use of real-world evidence in regulatory decisions for rare diseases in the United States\u2014current status and future directions. Pharmacoepidemiol Drug Saf. 2020;29:1213\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1837_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0140-6736(98)05279-9","volume":"353","author":"KM Bushby","year":"1999","unstructured":"Bushby KM, Hill A, Steele JG. Failure of early diagnosis in symptomatic Duchenne muscular dystrophy. Lancet. 1999;353:557\u20138.","journal-title":"Lancet"},{"key":"1837_CR6","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/ejhg.2014.301","volume":"23","author":"SH Wong","year":"2015","unstructured":"Wong SH, McClaren BJ, Archibald AD, Weeks A, Langmaid T, Ryan MM, et al. A mixed methods study of age at diagnosis and diagnostic odyssey for Duchenne muscular dystrophy. Eur J Hum Genet. 2015;23:1294\u2013300.","journal-title":"Eur J Hum Genet"},{"key":"1837_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1177\/0883073818773029","volume":"33","author":"A Soim","year":"2018","unstructured":"Soim A, Smith MG, Kwon JM, Mann JR, Thomas S, Ciafaloni E, et al. Is there a delay in diagnosis of duchenne muscular dystrophy among preterm-born males? J Child Neurol. 2018;33:537\u201345.","journal-title":"J Child Neurol"},{"key":"1837_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.nmd.2017.02.006","volume":"27","author":"A D'Amico","year":"2017","unstructured":"D\u2019Amico A, Catteruccia M, Baranello G, Politano L, Govoni A, Previtali SC, et al. Diagnosis of Duchenne Muscular Dystrophy in Italy in the last decade: critical issues and areas for improvements. Neuromuscul Disord. 2017;27:447\u201351.","journal-title":"Neuromuscul Disord"},{"key":"1837_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12519-017-0036-3","volume":"13","author":"Q Ke","year":"2017","unstructured":"Ke Q, Zhao ZY, Griggs R, Wiley V, Connolly A, Kwon J, et al. Newborn screening for Duchenne muscular dystrophy in China: follow-up diagnosis and subsequent treatment. World J Pediatr. 2017;13:197\u2013201.","journal-title":"World J Pediatr"},{"key":"1837_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, et al. The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015;36:395\u2013402.","journal-title":"Hum Mutat"},{"issue":"7894","key":"1837_CR11","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S0140-6736(74)90071-3","volume":"2","author":"DB Drachman","year":"1974","unstructured":"Drachman DB, Toyka KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet. 1974;2(7894):1409\u201312.","journal-title":"Lancet"},{"key":"1837_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391:451\u201361.","journal-title":"Lancet"},{"key":"1837_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77\u201393.","journal-title":"Lancet Neurol"},{"key":"1837_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251\u201367.","journal-title":"Lancet Neurol"},{"key":"1837_CR15","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","volume":"87","author":"RC Griggs","year":"2016","unstructured":"Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, et al. Efficacy and safety of deflazacort vs. prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87:2123\u201331.","journal-title":"Neurology"},{"key":"1837_CR16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/jnnp-2012-303902","volume":"84","author":"V Ricotti","year":"2013","unstructured":"Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry. 2013;84:698\u2013705.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1837_CR17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jamaneurol.2019.0242","volume":"76","author":"S Joseph","year":"2019","unstructured":"Joseph S, Wang C, Bushby K, Guglieri M, Horrocks I, Straub V, et al. Fractures and linear growth in a nationwide cohort of boys with Duchenne muscular dystrophy with and without glucocorticoid treatment: results from the UK NorthStar Database. JAMA Neurol. 2019;76:701\u20139.","journal-title":"JAMA Neurol"},{"key":"1837_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3233\/JND-140002","volume":"1","author":"JC Van den Bergen","year":"2014","unstructured":"Van den Bergen JC, Ginjaar HB, Niks EH, Aartsma-Rus A, Verschuuren JJ. Prolonged ambulation in Duchenne patients with a mutation amenable to exon 44 skipping. J Neuromuscul Dis. 2014;1:91\u20134.","journal-title":"J Neuromuscul Dis"},{"key":"1837_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1212\/WNL.0000000000002891","volume":"87","author":"L Bello","year":"2016","unstructured":"Bello L, Morgenroth LP, Gordish-Dressman H, Hoffman EP, McDonald CM, Cirak S. DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Neurology. 2016;87:401\u20139.","journal-title":"Neurology"},{"key":"1837_CR20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/jhg.2014.36","volume":"59","author":"EK Dwianingsih","year":"2014","unstructured":"Dwianingsih EK, Malueka RG, Nishida A, Itoh K, Lee T, Yagi M, et al. A novel splicing silencer generated by DMD exon 45 deletion junction could explain upstream exon 44 skipping that modifies dystrophinopathy. J Hum Genet. 2014;59:423\u20139.","journal-title":"J Hum Genet"},{"key":"1837_CR21","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/humu.23561","volume":"39","author":"RT Wang","year":"2018","unstructured":"Wang RT, Barthelemy F, Martin AS, Douine ED, Eskin A, Lucas A, et al. DMD genotype correlations from the Duchenne Registry: endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype. Hum Mutat. 2018;39:1193\u2013202.","journal-title":"Hum Mutat"},{"key":"1837_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00439-019-02107-4","volume":"139","author":"M Okubo","year":"2020","unstructured":"Okubo M, Noguchi S, Hayashi S, Nakamura H, Komaki H, Matsuo M, et al. Exon skipping induced by nonsense\/frameshift mutations in DMD gene results in Becker muscular dystrophy. Hum Genet. 2020;139:247\u201355.","journal-title":"Hum Genet"},{"key":"1837_CR23","doi-asserted-by":"publisher","first-page":"e83400","DOI":"10.1371\/journal.pone.0083400","volume":"9","author":"M Pane","year":"2014","unstructured":"Pane M, Mazzone ES, Sormani MP, Messina S, Vita GL, Fanelli L, et al. 6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes. PLoS ONE. 2014;9:e83400.","journal-title":"PLoS ONE"},{"key":"1837_CR24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 2018;17:445\u201355.","journal-title":"Lancet Neurol"},{"key":"1837_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.nmd.2016.11.012","volume":"27","author":"T Saito","year":"2017","unstructured":"Saito T, Kawai M, Kimura E, Ogata K, Takahashi T, Kobayashi M, et al. Study of Duchenne muscular dystrophy long-term survivors aged 40 years and older living in specialized institutions in Japan. Neuromuscul Disord. 2017;27:107\u201314.","journal-title":"Neuromuscul Disord"},{"key":"1837_CR26","first-page":"204","volume":"3","author":"EX Xu","year":"2015","unstructured":"Xu EX. Professor Shi-Wen Wu: One City, One Doctor-building up the national DMD registry network. Ann Transl Med. 2015;3:204.","journal-title":"Ann Transl Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01837-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01837-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01837-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T18:26:00Z","timestamp":1619634360000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01837-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1837"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01837-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"30 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by ethics committee of General Hospital of the Chinese People's Armed Police Forces (No.2015003). Written or online informed consent was obtained from patients or their legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consents for publication were obtained from the patients and\/or their parents or their legal guardians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"188"}}